Grey Matters Health Inc. is a clinical-stage pharmaceutical company focused on developing therapeutic drugs in the healthcare sector. The company faces significant concerns, including a low financial health score of 42/100, negative return on equity (-40.1%) and return on assets (-13.3%), indicating operational challenges. Additionally, a current ratio of 0.13 suggests liquidity issues, while a debt-to-equity ratio of 0.44 reflects moderate leverage. Overall, while the company is in a promising industry, its financial metrics raise red flags that potential investors should consider carefully.
Loading financial metrics...
Company has $42K in cash but burned $364K last quarter. At this burn rate, only 0.1 quarters of runway remain without additional financing.
Company posted a loss of $-2.2M over the last year, representing Infinity% of revenue.
Debt of $779K is 18.7x the company's cash position of $42K.
Operating cash flow has been negative for 3 consecutive quarters, burning $1.5M over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q3 (May 31, 2026)